Sana Biotechnology, Inc. Facility Costs
Sana Biotechnology, Inc. (SANA) reported Facility Costs of $10.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FacilityCosts · last filed 2026-08-10
- Sana Biotechnology, Inc. facility costs for the quarter ending 2026-06-30 was $10.37M, a 4.52% decline year-over-year.
- Sana Biotechnology, Inc. facility costs for the quarter ending 2026-03-31 was $10.48M, a 6.70% decline year-over-year.
- Sana Biotechnology, Inc. facility costs for the quarter ending 2025-12-31 was $28.51M, a 8.53% decline year-over-year.
- Sana Biotechnology, Inc. facility costs for the quarter ending 2025-09-30 was $5.41M, a 11.13% decline year-over-year.
- Sana Biotechnology, Inc. facility costs for fiscal 2025 was $44.25M, a 10.47% decline from fiscal 2024.
- Sana Biotechnology, Inc. facility costs for fiscal 2024 was $49.43M, a 9.76% decline from fiscal 2023.
- Sana Biotechnology, Inc. facility costs for fiscal 2023 was $54.78M, a 11.37% increase from fiscal 2022.
- Sana Biotechnology, Inc. facility costs for fiscal 2022 was $49.19M.
| Period end | Facility Costs 3 month | Facility Costs 3 month as first filed | Facility Costs 6 month | Facility Costs 6 month as first filed | Facility Costs 9 month | Facility Costs 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10.37M 10-Q · filed 2026-08-10 | $20.84M 10-Q · filed 2026-08-10 | $49.36M derived: sum of 3 quarters · filed 2026-08-10 | $54.76M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $10.48M 10-Q · filed 2026-05-11 | $38.99M derived: sum of 2 quarters · filed 2026-05-11 | $44.40M derived: sum of 3 quarters · filed 2026-05-11 | $55.25M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $28.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $33.92M derived: sum of 2 quarters · filed 2026-03-03 | $44.77M derived: sum of 3 quarters · filed 2026-08-10 | $44.25M 10-K · filed 2026-03-03 | ||
| 2025-09-30 | $5.41M 10-Q · filed 2025-11-06 | $16.26M derived: sum of 2 quarters · filed 2026-08-10 | $15.74M 10-Q · filed 2025-11-06 | $58.67M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $10.86M 10-Q · filed 2026-08-10 | $4.83M 10-Q · filed 2025-08-11 | $22.57M 10-Q · filed 2026-08-10 | $10.34M 10-Q · filed 2025-08-11 | $53.26M derived: sum of 3 quarters · filed 2026-08-10 | $59.34M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $11.23M 10-Q · filed 2026-05-11 | $42.40M derived: sum of 2 quarters · filed 2026-05-11 | $48.49M derived: sum of 3 quarters · filed 2026-05-11 | $55.00M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $31.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $37.26M derived: sum of 2 quarters · filed 2026-03-03 | $43.77M derived: sum of 3 quarters · filed 2026-03-03 | $49.43M 10-K · filed 2026-03-03 | ||
| 2024-09-30 | $6.08M 10-Q · filed 2025-11-06 | $12.60M derived: sum of 2 quarters · filed 2025-11-06 | $18.26M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $6.51M 10-Q · filed 2025-08-11 | $12.17M 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | $12.11M 10-Q · filed 2025-05-08 | |||||
| 2023-12-31 | $54.78M 10-K · filed 2026-03-03 | |||||
| 2022-12-31 | $49.19M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |